TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

How to Trade Red-Hot Gold While Everyone Obsesses Over Bitcoin
STOCKS

These Are the Hottest Stocks on the Planet Wednesday: URBN, TGT, PSTI, CSCO

PRESS RELEASES

Pluristem Announces Uplisting To The Nasdaq Global Market®

PRESS RELEASES

Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D To Expand Pluristem's ARDS Associated With COVID-19 Program To Mexico

PRESS RELEASES

Pluristem Announces DMC Recommendation Following Interim Analysis Of Its Phase III CLI Study

PRESS RELEASES

Pluristem To Present Initial Results From Its Phase I HCT Study With PLX-R18 Demonstrating Safety And Efficacy At The ASH Annual Meeting

PRESS RELEASES

Pluristem Announces Clearance To Move Forward With Enrollment For Cohort II In An Investigator-Led Phase I/II Chronic Graft Vs Host Disease Study

PRESS RELEASES

Pluristem Expands Its Phase II COVID-19 European Clinical Trial To Israel

PRESS RELEASES

Abu Dhabi Stem Cells Center And Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event

PRESS RELEASES

Pluristem CEO Issues Shareholder Update

PRESS RELEASES

Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside Of Clinical Trial

PRESS RELEASES

Pluristem Announces End Of Patient Enrollment In Its Phase I Hematology Study

PRESS RELEASES

Pluristem And Abu Dhabi Stem Cells Center Sign MOU To Collaborate In The Development Of Cell Therapies And Regenerative Medicines For The Treatment Of Severe Diseases Including COVID-19

PRESS RELEASES

Pluristem Expands Its COVID-19 Program To Europe, Receives PEI Clearance To Commence Phase II Study In Germany

PRESS RELEASES

Pluristem CEO Issues Shareholder Update On Clinical Programs

PRESS RELEASES

Pluristem Announces Activation Of Clinical Sites And Commencement Of Patient Enrollment In U.S. FDA Phase II COVID-19 ARDS Trial

PRESS RELEASES

Pluristem Joins Forces With CRISPR-IL National Consortium To Advance Development Of Cutting-Edge Genome Editing Solutions For Life Science Products

PRESS RELEASES

U.S. FDA Clears Pluristem's IND Application For Phase II COVID-19 Study

PRESS RELEASES

Pluristem Announces Pricing Of Its Registered Direct Offering For Aggregate Proceeds Of $15 Million

PRESS RELEASES

Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank's €50 Million Financing

PRESS RELEASES

EIB Signs Collaboration With Israel Innovation Authority And €50 Million Financing Agreement With Pluristem To Develop Therapies For COVID-19 And Other Unmet Medical Needs

PRESS RELEASES

The European Investment Bank (EIB), EU Delegation To Israel, The Israel Innovation Authority, And Pluristem Cordially Invite The Public To An Online Signing Ceremony On April 30, 2020

PRESS RELEASES

Pluristem Secures €50 Million Non-Dilutive Financing From The European Investment Bank To Support Its COVID-19 Project And Phase III Studies

PRESS RELEASES

Pluristem Expands Its Compassionate Use Program: Treated First COVID-19 Patient In U.S. Under FDA Single Patient Expanded Access Program

PRESS RELEASES

Pluristem Reports Preliminary Data From Its COVID-19 Compassionate Use Program, Treating Seven Patients With Acute Respiratory Failure

PRESS RELEASES

Pluristem Treated First Three COVID-19 Patients In Israel Under Compassionate Use